Literature DB >> 23949740

Changes of QTc interval after opioid switching to oral methadone.

Sebastiano Mercadante1, Giovanna Prestia, Claudio Adile, Alessandra Casuccio.   

Abstract

A consecutive sample of patients who were switched from strong opioids to methadone in a period of 1 year was surveyed. QTc was assessed before switching (T0) and after achieving adequate analgesia and an acceptable level of adverse effects (Ts). Twenty-eight of 33 patients were switched to methadone successfully. The mean initial methadone doses at T0 were 67.1 mg/day (SD ±80.2, range 12-390). The mean QTc interval at T0 was 400 ms (SD ±30, range 330-450). The mean QTc interval at Ts (median 5 days) was 430 ms (SD ±26, range 390-500). The difference (7.7 %) was significant (p < 0.0005). Only two patients had a QTc of 500 ms. No serious arrhythmia was observed. At the linear regression analysis, there was no significant association between mean opioid doses expressed as oral morphine equivalents and QTc at T0 (p = 0.428), nor between mean methadone doses and QTc at Ts (p = 0.315). No age differences were found with previous opioid doses (p = 0.917), methadone doses (p = 0.613), QTc at T0 (p = 0.173), QTc at Ts (p = 0.297), and final opioid-methadone conversion ratio (p = 0.064). While methadone used for opioids switching seems to be an optimal choice to improve the opioid response in patients poorly responsive to the previous opioid, the possible QTc prolongation should be of concern despite not producing clinical consequences in this group of patients. A larger number of patients should be assessed to quantify the risk of serious arrhythmia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23949740     DOI: 10.1007/s00520-013-1928-y

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  26 in total

1.  Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy.

Authors:  Andrew K Roy; Catherine McCarthy; Gareth Kiernan; Catherine McGorrian; Eamon Keenan; Niall G Mahon; Brion Sweeney
Journal:  Addiction       Date:  2012-02-28       Impact factor: 6.526

Review 2.  Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.

Authors:  Augusto Caraceni; Geoffrey Hanks; Stein Kaasa; Michael I Bennett; Cinzia Brunelli; Nathan Cherny; Ola Dale; Franco De Conno; Marie Fallon; Magdi Hanna; Dagny Faksvåg Haugen; Gitte Juhl; Samuel King; Pål Klepstad; Eivor A Laugsand; Marco Maltoni; Sebastiano Mercadante; Maria Nabal; Alessandra Pigni; Lukas Radbruch; Colette Reid; Per Sjogren; Patrick C Stone; Davide Tassinari; Giovambattista Zeppetella
Journal:  Lancet Oncol       Date:  2012-02       Impact factor: 41.316

3.  A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients.

Authors:  J Florian; C E Garnett; S C Nallani; B A Rappaport; D C Throckmorton
Journal:  Clin Pharmacol Ther       Date:  2012-02-29       Impact factor: 6.875

4.  Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: A prospective 9-month follow-up study.

Authors:  Olav Magnus S Fredheim; Petter C Borchgrevink; Lars Hegrenaes; Stein Kaasa; Ola Dale; Pål Klepstad
Journal:  J Pain Symptom Manage       Date:  2006-08       Impact factor: 3.612

5.  Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study.

Authors:  Einat Peles; Gershon Bodner; Mary Jeanne Kreek; Vera Rados; Miriam Adelson
Journal:  Addiction       Date:  2007-02       Impact factor: 6.526

6.  Measurement of QTc in patients receiving chronic methadone therapy.

Authors:  Ricardo A Cruciani; Ryuichi Sekine; Peter Homel; David Lussier; Ysmael Yap; Yukako Suzuki; Paul Schweitzer; Stanley R Yancovitz; Jeanne A Lapin; Lauren Shaiova; Robert G Sheu; Russell K Portenoy
Journal:  J Pain Symptom Manage       Date:  2005-04       Impact factor: 3.612

7.  QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.

Authors:  Ellen C Pearson; Raymond L Woosley
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-11       Impact factor: 2.890

8.  Fluctuating QTc interval in an asymptomatic patient treated with methadone for chronic pain.

Authors:  Katherine Ower; Patricia Morley-Forster; Dwight Moulin
Journal:  J Opioid Manag       Date:  2005 May-Jun

9.  Heterogeneous impact of methadone on the QTc interval: what are the practical implications?

Authors:  Mori J Krantz
Journal:  J Addict Dis       Date:  2008

Review 10.  Methadone: to ECG or not to ECG...That is still the question.

Authors:  Ricardo A Cruciani
Journal:  J Pain Symptom Manage       Date:  2008-04-28       Impact factor: 3.612

View more
  2 in total

Review 1.  Effects of opioid receptor agonist and antagonist medications on electrocardiogram changes and presentation of cardiac arrhythmia: review article.

Authors:  Farshid Etaee; Morgan Tobin; Suchith Vuppala; Alireza Komaki; Brian P Delisle; Luigi Di Biase; John N Catanzaro; Andrea Natale; Claude S Elayi
Journal:  J Interv Card Electrophysiol       Date:  2021-10-21       Impact factor: 1.900

2.  QT Interval Prolongation in the Pediatric Oncologic Population on Methadone.

Authors:  Jenna A Piccininni; James S Killinger; Hoda T Hammad; Linda M Gerber; Jeffrey D Dayton
Journal:  J Pediatr Hematol Oncol       Date:  2020-03       Impact factor: 1.170

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.